Pressure BioSciences, Inc. Announces Initial Equity Research Coverage by Zacks Investment Research

SOUTH EASTON, Mass., Aug. 18, 2010 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (Nasdaq:PBIO) ("PBI" or the "Company") today announced that Zacks Investment Research ("Zacks") has initiated coverage on the Company, effective August 16, 2010. Zacks is a leading provider of independent equity research.

Copies of this research report can be obtained by contacting Mr. Grant Zeng, CFA at Zacks Equity Research, 111 North Canal Street, Chicago, IL, 60606 by telephone (312-630-9880 x9466) or email (gzeng@zacks.com), or by contacting Zacks directly through their website (www.zacks.com).

Any opinions, judgments, estimates, or forecasts regarding the Company's historical or predicted performance or operations made by Zacks are theirs alone and do not represent opinions, judgments, estimates, or forecasts of the Company or its management. The Company does not by its reference to the research prepared by Zacks imply its endorsement or adoption of or concurrence with such information, conclusions, or recommendations.

About Zacks:

Founded in 1978 in Chicago, Zacks Investment Research, Inc. is one of the largest independent investment research and consulting firms in the United States. With 30 years of experience, dedicated to providing clients with the highest standards of services, Zacks has become an industry leader in providing institutional and individual investors with the analytical tools and financial information necessary to the success of their investment process.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a NASDAQ Capital Markets listed company focused on the development and sale of instrumentation and consumables based on a novel, enabling technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 14 US and 10 foreign patents covering multiple applications of PCT in the life sciences field, including genomic and proteomic sample preparation, pathogen inactivation, the control of chemical reactions, immunodiagnostics, and protein purification. PBI currently focuses its efforts on the development and sale of PCT-enhanced enzymatic digestion products designed specifically for the mass spectrometry marketplace, as well as sample preparation products for biomarker discovery, soil and plant biology, forensics, histology, and counter-bioterror applications.

Visit us at our website http://www.pressurebiosciences.com

CONTACT:  Pressure BioSciences, Inc.
          Investor Contacts:
          Richard T. Schumacher, President & CEO
          R. Wayne Fritzsche, Chairman
          (508) 230-1828

Released August 18, 2010